Mobile Health Strategy for Premature Birth
What You Need to Know Before You Apply
What is the purpose of this trial?
Preterm births are defined as delivery prior to 37 weeks gestation and account for 35% of infant deaths in the first year of life. Early preterm birth are deliveries prior to 32 weeks gestation and account for more than 70% of neonatal deaths and 36.1% of overall infant mortality. Women who have delivered a preterm infant and who have a short pregnancy interval (time between giving birth and subsequent conception) have an increased risk of preterm birth in subsequent pregnancies. The investigators hope to understand if a mobile health strategy can be used to reduce spontaneous preterm births via improved patient engagement, care coordination, and adherence to recommended care vs a traditional paper-based health strategy.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
Is the PretermConnect app safe for use in humans?
How is the PretermConnect app treatment different from other treatments for premature birth?
The PretermConnect app is unique because it uses mobile technology to educate and support mothers of premature infants, helping them prioritize their health and their babies' health. Unlike traditional treatments, it provides remote monitoring and social support, aiming to reduce social disadvantages and improve outcomes for both mothers and infants.34567
What data supports the effectiveness of the PretermConnect App treatment for premature birth?
Who Is on the Research Team?
C. Jason Wang, MD, PhD
Principal Investigator
Stanford University
Are You a Good Fit for This Trial?
This trial is for women aged 16-50 who have had a preterm infant and own a mobile phone. They must be able to read and understand English, with their child previously in neonatal care due to premature birth. Women without prior preterm births or those without a mobile phone are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive health education via a mobile app or paper-based strategy to reduce the risk of recurrent preterm births
Follow-up
Participants are monitored for outcomes such as inter-pregnancy interval, postpartum depression, and mother-infant bonding
What Are the Treatments Tested in This Trial?
Interventions
- Use of PretermConnect App
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor
University of Pittsburgh Medical Center
Collaborator
Children's Hospital of Philadelphia
Collaborator